Newswire (Published: Sunday, November 5, 2017, 10:01:00 PM CST, Received: Thursday, November 2, 2017, 2:31:04 PM CDT)

Word Count: 620

By a News Reporter-Staff News Editor at Clinical Trials Week -- Stratasys (NASDAQ: SSYS), a global leader in applied additive technology solutions, announced a new clinical study is being conducted with the New York University (NYU) School of Medicine - aimed at advancing diagnosis and treatment of complex kidney and prostate tumors through imaging and 3D printing. These patient-specific 3D models of organs and their associated pathologies may empower surgeons and researchers to conduct more accurate pre-operative assessment and inter-operative guidance, potentially improving surgical outcomes (see also Oncology - Prostate Cancer).

Under the randomized, controlled study, Wake and her research team are 3D printing kidney and prostate cancer models for a sample of the participating 300 patients - measuring the specific impact each has on pre-surgical planning versus traditional 2D visualization approaches. Subjects are separated into three treatment categories to analyze and compare conventional pre-operative 2D imaging, augmented reality models, and next-generation 3D printed models.

"3D printing holds a lot of potential in assisting with surgical planning, and as surgeons, we are always looking at ways to improve outcomes for our patients," says study co-author William C. Huang, MD, associate professor of urology at NYU School of Medicine. "We are pleased to be leading a study examining how 3D-printed models may improve the surgical planning process and ultimately impact patient care."

"Surgeons and hospitals continuously search for ways to improve the quality of patient care while also reining in procedural costs. In case studies and small trials, 3D printed patient-specific models have shown tremendous potential to improve clinical outcomes and cost savings," said Scott Rader, GM of Healthcare Solutions at Stratasys. "This clinical study will be one of the first large-scale studies that can finally quantify the impact of 3D printing."

With its unique ability to produce parts in over 360,000 colors, textures, gradients, and transparencies - the Stratasys J750 3D Printer delivers medical models with a broad array of characteristics that replicate the look, feel and function of organic structures. Built directly from patient scans, these models match the widest array of medical properties - from soft tissue to hard bone. Advanced modeling not only guides surgeons in the operating room, but enables patients to better visualize proposed treatments and course of care.

Moving forward, the clinical study is expected to continue into 2018. During the next phase of the project, researchers will begin to explore quantitative patient outcomes.

Stratasys (NASDAQ: SSYS) is a global leader in applied additive technology solutions for industries including Aerospace, Automotive, Healthcare, Consumer Products and Education. For nearly 30 years, a deep and ongoing focus on customers' business requirements has fueled purposeful innovations-1,200 granted and pending additive technology patents to date-that create new value across product lifecycle processes, from design prototypes to manufacturing tools and final production parts. The Stratasys 3D printing ecosystem of solutions and expertise-advanced materials; software with voxel level control; precise, repeatable and reliable FDM and PolyJet 3D printers; application-based expert services; on-demand parts and industry-defining partnerships-works to ensure seamless integration into each customer's evolving workflow. Fulfilling the real-world potential of additive, Stratasys delivers breakthrough industry-specific applications that accelerate business processes, optimize value chains and drive business performance improvements for thousands of future-ready leaders around the world.Corporate Headquarters: Minneapolis, Minnesota and Rehovot, Israel.Online at:, and LinkedIn.

Stratasys is a registered trademark, and the Stratasys J750 and Stratasys signet are trademarks or registered trademarks of Stratasys Ltd. and or its subsidiaries or affiliates. All other trademarks belong to their respective owners.

Keywords for this news article include: Stratasys, Technology, Prostatic Neoplasms, Oncology - Prostate Cancer.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


Stratasys Limited
Microsoft Corporation


            Application Software
                  Simulation Software


North America
United States


Science and Technology
      Scientific Research
            Healthcare Technology
            Technology Trends
Business and Commerce
      Manufacturing Operations
            Additive Manufacturing
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Health Sciences
            Healthcare Technology
            Medical Research
            Pharmaceutical Development
      Medical Specialties and Practices
      Medical and Pharmaceutical Regulation
            Drug and Device Approval Process
Life and Society